CVKD
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$2.09-3.24%
Price as of Jul 20, 2026
CVKD financials
Cadrenal Therapeutics, Inc. Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $1.3K |
| Gross profit | $0.00 | $0.00 | $0.00 | -$1.3K |
| Operating expenses | $13.5M | $11.0M | $7.6M | $2.7M |
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M |
| EBITDA | -$13.2M | -$10.6M | -$8.3M | -$6.6M |
| Basic EPS | $-6.64 | $-8.73 | $-9.63 | $-8.66 |
| Diluted EPS | $-6.64 | $-8.73 | $-9.63 | $-8.66 |
| Balance sheet | ||||
| Cash & equivalents | $4.0M | $10.0M | $8.4M | $32.6K |
| Total assets | $4.3M | $10.1M | $8.5M | $778.2K |
| Total liabilities | $1.6M | $2.7M | $826.9K | $6.3M |
| Stockholders’ equity | $2.7M | $7.4M | $7.7M | -$5.6M |
| Total debt | $0.00 | $0.00 | $21.4K | $640.7K |
| Net debt | -$4.0M | -$10.0M | -$8.4M | $608.1K |
| Cash flow | ||||
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Capital expenditure | -$5.1K | -$6.5K | -$3.3K | $0.00 |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$291.9K | $0.00 | $0.00 | $0.00 |